Autotaxin Structure-activity Relationships Revealed Through Lysophosphatidylcholine Analogs

Overview

Journal Bioorg Med Chem

Specialties Biochemistry
Chemistry

Date 2009 Apr 7

PMID 19345587

Citations 12

Authors

E Jeffrey North

Daniel A Osborne

Peter K Bridson

Daniel L Baker

Abby L Parrill

Affiliations

Soon will be listed here.

Abstract

Autotaxin (ATX) catalyzes the hydrolysis of lysophosphatidylcholine (LPC) to form the bioactive lipid lysophosphatidic acid (LPA). LPA stimulates cell proliferation, cell survival, and cell migration and is involved in obesity, rheumatoid arthritis, neuropathic pain, atherosclerosis and various cancers, suggesting that ATX inhibitors have broad therapeutic potential. Product feedback inhibition of ATX by LPA has stimulated structure-activity studies focused on LPA analogs. However, LPA displays mixed mode inhibition, indicating that it can bind to both the enzyme and the enzyme-substrate complex. This suggests that LPA may not interact solely with the catalytic site. In this report we have prepared LPC analogs to help map out substrate structure-activity relationships. The structural variances include length and unsaturation of the fatty tail, choline and polar linker presence, acyl versus ether linkage of the hydrocarbon chain, and methylene and nitrogen replacement of the choline oxygen. All LPC analogs were assayed in competition with the synthetic substrate, FS-3, to show the preference ATX has for each alteration. Choline presence and methylene replacement of the choline oxygen were detrimental to ATX recognition. These findings provide insights into the structure of the enzyme in the vicinity of the catalytic site as well as suggesting that ATX produces rate enhancement, at least in part, by substrate destabilization.

Citing Articles

Solid-phase microextraction of endogenous metabolites from intact tissue validated using a Biocrates standard reference method kit.

Jiang R, Jaroch K, Pawliszyn J J Pharm Anal. 2023; 13(1):55-62.

PMID: 36816540 PMC: 9937786. DOI: 10.1016/j.jpha.2022.09.002.

Identification of a differential metabolite-based signature in patients with late-stage knee osteoarthritis.

Rockel J, Layeghifard M, Rampersaud Y, Perruccio A, Mahomed N, Davey J Osteoarthr Cartil Open. 2022; 4(3):100258.

PMID: 36474953 PMC: 9718221. DOI: 10.1016/j.ocarto.2022.100258.

Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test.

Kenny L, Thomas G, Poston L, Myers J, Simpson N, McCarthy F PLoS One. 2020; 15(12):e0244369.

PMID: 33370367 PMC: 7769282. DOI: 10.1371/journal.pone.0244369.

Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.

Ragle L, Palanisamy D, Joe M, Stein R, Norman D, Tigyi G Bioorg Med Chem. 2016; 24(19):4660-4674.

PMID: 27544588 PMC: 5023007. DOI: 10.1016/j.bmc.2016.08.004.

Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.

Black K, Berdyshev E, Bain G, Castelino F, Shea B, Probst C FASEB J. 2016; 30(6):2435-50.

PMID: 27006447 PMC: 4871797. DOI: 10.1096/fj.201500197R.

References

van Meeteren L, Ruurs P, Christodoulou E, Goding J, Takakusa H, Kikuchi K . Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem. 2005; 280(22):21155-61. DOI: 10.1074/jbc.M413183200. View

Murakami M, Shiraishi A, Tabata K, Fujita N . Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2008; 371(4):707-12. DOI: 10.1016/j.bbrc.2008.04.145. View

Pasternack S, von Kugelgen I, Al Aboud K, Lee Y, Ruschendorf F, Voss K . G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet. 2008; 40(3):329-34. DOI: 10.1038/ng.84. View

McIntyre T, Pontsler A, Silva A, St Hilaire A, Xu Y, Hinshaw J . Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci U S A. 2002; 100(1):131-6. PMC: 140905. DOI: 10.1073/pnas.0135855100. View

Clair T, Koh E, Ptaszynska M, Bandle R, Liotta L, Schiffmann E . L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin. Lipids Health Dis. 2005; 4:5. PMC: 554093. DOI: 10.1186/1476-511X-4-5. View

Gijsbers R, Ceulemans H, Stalmans W, Bollen M . Structural and catalytic similarities between nucleotide pyrophosphatases/phosphodiesterases and alkaline phosphatases. J Biol Chem. 2000; 276(2):1361-8. DOI: 10.1074/jbc.M007552200. View

van Meeteren L, Moolenaar W . Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res. 2007; 46(2):145-60. DOI: 10.1016/j.plipres.2007.02.001. View

Ferguson C, Bigman C, Richardson R, van Meeteren L, Moolenaar W, Prestwich G . Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org Lett. 2006; 8(10):2023-6. PMC: 2528860. DOI: 10.1021/ol060414i. View

Rother E, Brandl R, Baker D, Goyal P, Gebhard H, Tigyi G . Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation. 2003; 108(6):741-7. DOI: 10.1161/01.CIR.0000083715.37658.C4. View

10.

Tabata K, Baba K, Shiraishi A, Ito M, Fujita N . The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2007; 363(3):861-6. DOI: 10.1016/j.bbrc.2007.09.063. View

11.

Cui P, Tomsig J, McCalmont W, Lee S, Becker C, Lynch K . Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors. Bioorg Med Chem Lett. 2007; 17(6):1634-40. PMC: 4116752. DOI: 10.1016/j.bmcl.2006.12.114. View

12.

Stracke M, Krutzsch H, Unsworth E, Arestad A, Cioce V, Schiffmann E . Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem. 1992; 267(4):2524-9. View

13.

Jiang G, Xu Y, Fujiwara Y, Tsukahara T, Tsukahara R, Gajewiak J . Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem. 2007; 2(5):679-90. PMC: 3505595. DOI: 10.1002/cmdc.200600280. View

14.

Parrill A . Lysophospholipid interactions with protein targets. Biochim Biophys Acta. 2008; 1781(9):540-6. PMC: 2564851. DOI: 10.1016/j.bbalip.2008.04.011. View

15.

Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R . Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem. 2004; 279(17):17634-9. DOI: 10.1074/jbc.M313927200. View

16.

Lee C, Rivera R, Gardell S, Dubin A, Chun J . GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem. 2006; 281(33):23589-97. DOI: 10.1074/jbc.M603670200. View

17.

Jansen S, Callewaert N, Dewerte I, Andries M, Ceulemans H, Bollen M . An essential oligomannosidic glycan chain in the catalytic domain of autotaxin, a secreted lysophospholipase-D. J Biol Chem. 2007; 282(15):11084-91. DOI: 10.1074/jbc.M611503200. View

18.

Chen L, Wu L, Otaka A, Smyth M, Roller P, Burke Jr T . Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases?. Biochem Biophys Res Commun. 1995; 216(3):976-84. DOI: 10.1006/bbrc.1995.2716. View

19.

Durgam G, Virag T, Walker M, Tsukahara R, Yasuda S, Liliom K . Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem. 2005; 48(15):4919-30. DOI: 10.1021/jm049609r. View

20.

Boucher J, Quilliot D, Praderes J, Simon M, Gres S, Guigne C . Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia. 2005; 48(3):569-77. PMC: 1885462. DOI: 10.1007/s00125-004-1660-8. View